AR-V7 as a Biomarker in CRPC

May 19, 2015
Emmanuel S. Antonarakis, MBBCh

Special Reports, Genitourinary (Issue 2), Issue 2

Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine, discusses the potential of AR-V7 as a biomarker in early stage castration-resistant prostate cancer (CRPC).

Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine, discusses the potential of AR-V7 as a biomarker in early stage castration-resistant prostate cancer (CRPC).

<<<

View more from the GU Cancers Special Report